← Back to Clinical Trials
Recruiting NCT06970288

NCT06970288 Effectiveness of Introducing Ultra-High B-Value Diffusion-Weighted Imaging as a Modified Abbreviated Protocol for Breast Cancer Detection

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06970288
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Breast Carcinoma
Study Type OBSERVATIONAL
Enrollment 85 participants
Start Date 2025-05-10
Primary Completion 2026-11-15

Eligibility & Interventions

Sex Female only
Min Age 30 Years
Max Age 50 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 85 participants in total. It began in 2025-05-10 with a primary completion date of 2026-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to evaluate the added value of non-contrast abbreviated MRI protocol featuring ultra-high B value Diffusion Weighted Imaging to detect, characterize suspicious breast lesions and avoid using contrast.

Eligibility Criteria

Inclusion Criteria: * • Women with suspicious breast mass (BIRADS 4a) * High risk women (Positive family history) * Women with suspicious axillary lymph nodes by Ultrasound * Women with dense breasts coming for MRI imaging. Exclusion Criteria: * • Contraindications to MRI * Pacemaker, cochlear implant, claustrophobia, ocular implants * Contraindications to contrast administration: * Elevated kidney functions * Women who haven't undergone reliable Mammogram \& Ultrasound * Women with prior treatment or intervention (e.g. biopsy) * Patients' refusal.

Contact & Investigator

Central Contact

Ahmed Mohamed Aly

✉ ahmedaly@med.asu.edu.eg

📞 +201273726233

Frequently Asked Questions

Who can join the NCT06970288 clinical trial?

This trial is open to female participants only, aged 30 Years or older, up to 50 Years, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06970288 currently recruiting?

Yes, NCT06970288 is actively recruiting participants. Contact the research team at ahmedaly@med.asu.edu.eg for enrollment information.

Where is the NCT06970288 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06970288 clinical trial?

NCT06970288 is sponsored by Ain Shams University. The trial plans to enroll 85 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology